Stephens & Co. Reiterates Overweight on Avid Bioservices, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Jacob Johnson has reiterated an Overweight rating on Avid Bioservices (NASDAQ:CDMO) and maintained a $12 price target.
September 10, 2024 | 1:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stephens & Co. has reiterated an Overweight rating for Avid Bioservices, maintaining a $12 price target, indicating confidence in the company's potential for growth.
The reiteration of an Overweight rating and maintenance of a $12 price target by Stephens & Co. suggests a positive outlook for Avid Bioservices. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100